Management of Clevudine-Resistant Chronic Hepatitis B: A Multicenter Cohort Study

키워드

참고문헌 (32)

1. Lee HS, "A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B", Hepatology, 43, pp.982~988 (2006)
2. Lee KS, "Clevudine therapy for 24 weeks further reduced serum hepatitis B virus DNA levels and increased ALT normalization rates without emergence of viral breakthrough than 12 weeks of clevudine therapy", Intervirology, 50, pp.296~302 (2007)
3. Yoo BC, "Twenty-four-week clevudine therapy showed potent and sustained antiviral activity in HBeAgpositive chronic hepatitis B", Hepatology, 45, pp.1172~1178 (2007)
4. Yoo BC, "Clevudine is highly efficacious in hepatitis B e antigen-negative chronic hepatitis B with durable off-therapy viral suppression", Hepatology, 46, pp.1041~1048 (2007)
5. 김민환, "만성 B형간염에서 클레부딘의 48주 치료 효과", Clinical and Molecular Hepatology, 15(3), pp.331~337 (2009), 대한간학회
6. Ko SY, "Clinical and virological responses to clevudine therapy in chronic hepatitis B patients: results at 1 year of an open-labelled prospective study", Antivir Ther, 14, pp.585~590 (2009)
7. 이헌주, "만성 B형간질환에서 핵산유사체 치료경험이 없는 환자와 라미부딘 경험자에서의 클레부딘 치료", Clinical and Molecular Hepatology, 15(2), pp.179~192 (2009), 대한간학회
8. Korean Association for the Study of the Liver, "KASL clinical practice guidelines: management of chronic hepatitis B", Clin Mol Hepatol, 18, pp.109~162 (2012)
9. Lee KS, "Korean Association for the Study of the Liver Guideline Committee. Management of chronic hepatitis", Korean J Hepatol, 13, pp.447~488 (2007)
10. Yim HJ, "Options for the management of antiviral resistance during hepatitis B therapy: reflections on battles over a decade.", Clin Mol Hepatol, 19, pp.195~209 (2013)
11. European Association for the Study of the Liver, "EASL clinical practice guidelines: management of chronic hepatitis B virus infection", J Hepatol, 57, pp.167~185 (2012)
12. Lee KS, "Clevudine therapy in patients with chronic hepatitis B", Korean J Hepatol, 15, pp.119~121 (2009)
13. Rapti I, "Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAgnegative chronic hepatitis B", Hepatology, 45, pp.307~313 (2007)
14. Yim HJ, "Adding adefovir vs. switching to entecavir for lamivudine-resistant chronic hepatitis B (ACE study): a 2-year follow-up randomized controlled trial", Liver Int, 33, pp.244~254 (2013)
15. Kim HJ, "Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy", J Gastroenterol Hepatol, 25, pp.1374~1380 (2010)
16. Ryu HJ, "Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B", J Med Virol, 82, pp.1835~1842 (2010)
17. Suzuki F, "Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B:randomized controlled trial in Japanese patients", J Gastroenterol Hepatol, 23, pp.1320~1326 (2008)
18. Dai CY, "Adefovir dipivoxil treatment of lamivudine-resistant chronic hepatitis B", Antiviral Res, 75, pp.146~151 (2007)
19. Peters MG, "Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudineresistant chronic hepatitis B", Gastroenterology, 126, pp.91~101 (2004)
20. Kim BK, "Clevudine myopathy in patients with chronic hepatitis B.", J Hepatol, 51, pp.829~834 (2009)
21. Seok JI, "Long-term therapy with clevudine for chronic hepatitis B can be associated with myopathy characterized by depletion of mitochondrial DNA", Hepatology, 49, pp.2080~2086 (2009)
22. Tak WY, "Clinical, biochemical, and pathological characteristics of clevudine-associated myopathy", J Hepatol, 53, pp.261~266 (2010)
23. Yoon EL, "Comparison of clevudine and entecavir for treatment-naïve patients with chronic hepatitis B virus infection: two-year follow-up data.", J Clin Gastroenterol, 45, pp.893~899 (2011)
24. Fung SK, "Drug insight: nucleoside and nucleotide analog inhibitors for hepatitis B", Nat Clin Pract Gastroenterol Hepatol, 1, pp.90~97 (2004)
25. Marcellin P, "Tenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis B", N Engl J Med, 359, pp.2442~2455 (2008)
26. Fung S, "Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B", Gastroenterology, 146, pp.980~988 (2014)
27. Berg T, "Tenofovir is effective alone or with emtricitabine in adefovir-treated patients with chronichepatitis B virus infection", Gastroenterology, 139, pp.1207~1217 (2010)
28. Lim YS, "Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial", Gut, 65, pp.1042~1051 (2016)
29. Patterson SJ, "Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B", Gut, 60, pp.247~254 (2011)
30. Lim YS, "Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure:results of a randomised tria", Gut, 65, pp.852~860 (2016)
31. 김효진, "Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients", The Korean Journal of Internal Medicine, 30(1), pp.32~41 (2015), 대한내과학회[DOI]
32. Yang DH, "Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients", World J Gastroenterol, 21, pp.2746~2753 (2015)

관련 논문AI추천